Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
10:33am, Thursday, 13'th Jun 2024
Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
08:58am, Wednesday, 12'th Jun 2024
RALEIGH, N.C.--(BUSINESS WIRE)--QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus.
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
08:00am, Wednesday, 12'th Jun 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the acquisition of Pro-ficiency with simulation-enabled solutions to expand and enhance the Company's offerings.
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
08:30am, Wednesday, 22'nd May 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Craig-Hallum's 21st Annual Institutional Investor Conference on May 29, in Minneapolis.
Simulations Plus (SLP) Launches GPX to Advance PBPK Modeling
02:21pm, Thursday, 16'th May 2024
Simulations Plus (SLP) unveils GastroPlus X, which significantly reduces time spent on model setup, data management, and reformatting results.
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
08:30am, Wednesday, 15'th May 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of the completely redesigned GastroPlusX (GPX), the next generation PBPK/PBBM modeling & simulation software.
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
01:53pm, Friday, 12'th Apr 2024
You may have heard about GPT-4 Turbo, Gemini, Llama or X's (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town.
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
10:10am, Monday, 08'th Apr 2024
For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
08:30am, Thursday, 04'th Apr 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
07:36am, Thursday, 04'th Apr 2024
Simulations Plus' (SLP) second-quarter fiscal 2024 top line is driven by higher revenues in the Software and Services business segments.
Simulations Plus, Inc. (SLP) Q2 2024 Earnings Call Transcript
11:15pm, Wednesday, 03'rd Apr 2024
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2023 Results Earnings Conference Call April 4, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief
Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
06:21pm, Wednesday, 03'rd Apr 2024
Simulations Plus (SLP) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.20 per share a year ago.
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
04:34pm, Wednesday, 03'rd Apr 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported earnings for its second quarter of fiscal year 2024. Total revenue for the quarter increased 16% to $18.3 million.
Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?
08:26am, Tuesday, 02'nd Apr 2024
Simulations Plus (SLP) fiscal second-quarter performance is likely to have benefited from momentum across Software and Services business segments.
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
04:06pm, Wednesday, 20'th Mar 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will hold a conference call to discuss the Company's 2nd quarter FY24 financial results on Wed, April 3, 2024, at 5pm EDT.
